X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ACTAVIS
Dec-14
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs80919,451-   
Low Rs50411,864-   
Sales per share (Unadj.) Rs281.13,502.5-  
Earnings per share (Unadj.) Rs41.4-437.1-  
Cash flow per share (Unadj.) Rs50.9321.3-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.47,596.8-  
Shares outstanding (eoy) m585.88265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.5 52.3%   
Avg P/E ratio x15.9-35.8 -44.3%  
P/CF ratio (eoy) x12.948.7 26.5%  
Price / Book Value ratio x3.32.1 159.8%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6304,163,324 9.2%   
No. of employees `00017.321.6 80.2%   
Total wages/salary Rs m21,3080-   
Avg. sales/employee Rs Th9,500.743,116.7 22.0%   
Avg. wages/employee Rs Th1,229.40-   
Avg. net profit/employee Rs Th1,397.9-5,380.5 -26.0%   
INCOME DATA
Net Sales Rs m164,666931,321 17.7%  
Other income Rs m1,020-2,324 -43.9%   
Total revenues Rs m165,686928,996 17.8%   
Gross profit Rs m37,718119,641 31.5%  
Depreciation Rs m5,580201,665 2.8%   
Interest Rs m77729,376 2.6%   
Profit before tax Rs m32,380-113,724 -28.5%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,342 0.0%   
Tax Rs m8,183-5,847 -140.0%   
Profit after tax Rs m24,229-116,219 -20.8%  
Gross profit margin %22.912.8 178.3%  
Effective tax rate %25.35.1 491.5%   
Net profit margin %14.7-12.5 -117.9%  
BALANCE SHEET DATA
Current assets Rs m121,878490,687 24.8%   
Current liabilities Rs m86,806357,855 24.3%   
Net working cap to sales %21.314.3 149.3%  
Current ratio x1.41.4 102.4%  
Inventory Days Days13058 223.9%  
Debtors Days Days6866 103.1%  
Net fixed assets Rs m81,037113,724 71.3%   
Share capital Rs m5860-   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,8042,020,000 5.8%   
Long term debt Rs m4,5121,058,520 0.4%   
Total assets Rs m211,0523,701,996 5.7%  
Interest coverage x42.7-2.9 -1,485.8%   
Debt to equity ratio x00.5 7.4%  
Sales to assets ratio x0.80.3 310.1%   
Return on assets %11.8-2.3 -505.1%  
Return on equity %20.7-5.8 -360.5%  
Return on capital %27.4-3.0 -908.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,548159,926 12.2%  
From Investments Rs m-19,570-382,924 5.1%  
From Financial Activity Rs m8,642215,148 4.0%  
Net Cashflow Rs m8,922-7,850 -113.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare AUROBINDO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  CIPLA  JUBILANT LIFE SCIENCES  STRIDES PHARMA SCIENCE  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 21, 2018 03:35 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ABBOTT INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS